Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
4 hedge funds and large institutions have $29.2K invested in Dermata Therapeutics Warrant in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
1.29% less ownership
Funds ownership: 2% → 0.71% (-1.3%)
20% less funds holding
Funds holding: 5 → 4 (-1)
79% less capital inflows, than outflows
Capital inflows: $41 | Capital outflows: $193
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$40 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$193 |
DRMAW Hedge Fund Activity: Q2 2024 in Review
4 of the 6,940 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q2 2024, worth a combined $29.2K — up 438% from $5.42K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DRMAW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $40. The largest seller was Armistice Capital, exiting entirely with an estimated $193 sold.
- 4 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q2 2024, down from 5 in Q1 2024.
- Funds reported $29.2K of Dermata Therapeutics Warrant stock for Q2 2024, up 438% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q2 2024 was UBS Group, an estimated $40 added.
- The largest Dermata Therapeutics Warrant seller in Q2 2024 was Armistice Capital, an estimated $193 sold.
Based on aggregated 13F filings for Q2 2024.